Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 52.91 USD -0.3% Market Closed
Market Cap: 9.8B USD
Have any thoughts about
Exact Sciences Corp?
Write Note

Exact Sciences Corp
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Exact Sciences Corp
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Exact Sciences Corp
NASDAQ:EXAS
Total Receivables
$264.8m
CAGR 3-Years
2%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Exact Sciences Corp
Glance View

Market Cap
9.8B USD
Industry
Biotechnology

Exact Sciences Corp. is a pioneering diagnostics company that focuses on the early detection and prevention of colorectal cancer, which is one of the deadliest cancers in the world. Founded in 1995 and based in Madison, Wisconsin, Exact Sciences made significant strides with its flagship product, Cologuard, the first non-invasive stool-based DNA test approved by the FDA for colorectal cancer screening. By combining advanced molecular biology and genetic testing, the company aims to enhance the efficiency and effectiveness of cancer screening processes, ultimately saving lives and reducing healthcare costs. This innovation has positioned Exact Sciences as a leader in preventive healthcare, catering to the growing demand for accessible and reliable cancer screening solutions in the U.S. and beyond. As the company expands its product portfolio, it is also actively working on additional tests to detect other types of cancers and diseases, demonstrating its commitment to broadening its impact in the health sector. Exact Sciences has engaged in strategic collaborations and acquisitions to accelerate growth and innovation, including partnerships with large biopharmaceutical companies and healthcare providers. For investors, Exact Sciences presents a compelling opportunity—a company at the forefront of a vital healthcare sector, with proven products, a robust pipeline, and a mission that resonates with the increasing emphasis on preventive medicine. With strong revenue growth and a dedicated focus on research and development, Exact Sciences is poised for a future where early intervention and personalized care become the norm.

EXAS Intrinsic Value
41.2 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Exact Sciences Corp's Total Receivables?
Total Receivables
264.8m USD

Based on the financial report for Sep 30, 2024, Exact Sciences Corp's Total Receivables amounts to 264.8m USD.

What is Exact Sciences Corp's Total Receivables growth rate?
Total Receivables CAGR 5Y
26%

Over the last year, the Total Receivables growth was 33%. The average annual Total Receivables growth rates for Exact Sciences Corp have been 2% over the past three years , 26% over the past five years .

Back to Top